Gene therapy ethics CER

Parallel case (not today's prompt): A patient carries a BRCA1 mutation that raises her lifetime breast cancer risk far above average. She could have a preventive (prophylactic) double mastectomy now, before any cancer appears, but the surgery is irreversible and carries its own risks. Should the care team recommend it? Study how this CER is built, then write your own on today's gene therapy question.\n\nClaim: The team should recommend the preventive double mastectomy for this BRCA1 carrier, because the benefit outweighs a risk we can prepare for.\n\nEvidence 1 (from my risk chart): A BRCA1 mutation raises lifetime breast cancer risk to roughly 55 to 72 percent, far above the general population rate of about 13 percent, and preventive mastectomy lowers that risk by about 90 percent or more.\n\nEvidence 2 (from my screening notes): The alternative, intensive surveillance with yearly MRI and mammography, catches cancer earlier but does not lower the chance of getting it, so it leaves the underlying high risk in place.\n\nReasoning that names the risk: The main risk is that surgery is permanent and can bring complications such as infection, loss of sensation, and the emotional weight of an irreversible change, and the patient might never have developed cancer at all. But because her inherited risk is so much higher than average, because surgery cuts that risk by roughly ninety percent, and because surveillance alone cannot lower the risk itself, the likely benefit of preventing a serious cancer tips the balance toward recommending the procedure, with counseling so the choice stays hers.\n\nBalance statement: I name the benefit (a large drop in a very high cancer risk), the risk (an irreversible surgery with real complications for a person who might never have gotten sick), and the reasoning (the size of the inherited risk plus the limits of surveillance) that tips it toward yes.